9 September 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx Pharmaceuticals" or the
"Company")
FLT3 Assay Ready for Phase I
Trials at MD Anderson
Hemogenyx Pharmaceuticals plc (LSE:
HEMO), a
clinical-stage biopharmaceutical group focused on developing
treatments for cancers and viral diseases, is pleased to announce
the successful completion of the development of a clinical-grade
assay ("Assay") designed to assess FLT3 protein expression in acute
myeloid leukemia ("AML") cells.
Assessing FLT3 protein expression in
AML cells is crucial for the accurate identification and
recruitment of patients for the imminent Phase I clinical trials of
the Company's HEMO-CAR-T product candidate. The trials are expected
to commence shortly at MD Anderson Cancer Center
("MD
Anderson"), one of the world's
most respected centers devoted exclusively to cancer patient care,
research, education and prevention. The Phase I clinical trials are
planned to expand to the University of Pennsylvania Medical Center
thereafter.
Dr
Vladislav Sandler, CEO and Co-Founder of Hemogenyx Pharmaceuticals,
commented:
"The completion of our FLT3 assay
marks a critical milestone in advancing our HEMO-CAR-T product
candidate into clinical trials. This Assay will ensure we can
accurately identify and recruit the right patients for the trials,
bringing us one step closer to providing a potentially life-saving
treatment for those battling AML. We are excited to begin our Phase
I trials imminently at MD Anderson Cancer Center, a leading
institution in cancer care, and look forward to expanding our
efforts to the University of Pennsylvania Medical
Center."
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
About Hemogenyx
Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a
publicly traded company (LSE: HEMO) headquartered in London, with
its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and
Immugenyx LLC, located in New York City at its state-of-the-art
research facility.
The Company is a clinical-stage
biopharmaceutical group developing new medicines and treatments for
life-threatening diseases. Hemogenyx Pharmaceuticals is developing
several distinct and complementary product candidates, as well as a
platform technology that it uses as an engine for novel product
development.
About
AML
AML, the most common type of acute
leukemia in adults, has poor survival rates (a five-year survival
rate of less than 30% in adults) and is currently treated using
chemotherapy, rather than the potentially more benign and effective
form of therapy being developed by Hemogenyx Pharmaceuticals. The
successful development of the new therapy for AML would have a
major impact on treatment and survival rates for the
disease.
About ALL
Acute Lymphoblastic Leukemia (ALL)
is a cancer of the blood and bone marrow that primarily affects
children, although it can also occur in adults. Unlike Acute
Myeloid Leukemia (AML), ALL is characterized by the rapid
proliferation of immature lymphocytes, a type of white blood cell.
ALL is the most common childhood cancer, representing approximately
25% of cancer diagnoses in children. It progresses quickly and
requires prompt treatment. While the overall prognosis for ALL
is generally more favorable than AML, certain subtypes remain
challenging to treat. Hemogenyx Pharmaceuticals is developing
innovative treatments specifically targeting a subset of ALL that
has proven particularly difficult to treat, especially in children.
The Company's R&D focuses on addressing the limitations of
current therapies and improving outcomes for patients with these
hard-to-treat forms of ALL.
About MD Anderson
The University of Texas MD Anderson
Cancer Center is one of the world's most respected centers devoted
exclusively to cancer patient care, research, education and
prevention. The mission of the MD Anderson is to eliminate cancer
in Texas, the USA, and the world through outstanding
programs that integrate patient care, research and
prevention, and through education for undergraduate and graduate
students, trainees, professionals, employees and the
public.